https://www.thelancet.com/action/sho...2821%2902183-8
"Effectiveness against SARS-CoV-2 infections waned during the
6 months of this study. Effectiveness against hospital
admissions in all age groups did not wane over the
duration of the study. These findings are consistent with
preliminary reports from the Israel Ministry of Health
and US Centers for Disease Control and Prevention
showing reductions in effectiveness of BNT162b2 against
infections 5 months or longer after being fully vaccinated,
but consistently high estimates against COVID-19-
related hospital admissions and severe disease up until
July, 2021.24–27 The most recent report from August, 2021,
from Israel, however, suggests that some reduction in
effectiveness against hospital admissions has been
observed among older people (≥65 years) roughly
6 months after receiving the second dose of BNT162b2.31
Thus, long-term effectiveness data against severe
outcomes should be continuously monitored in our
study population and globally. "
Our results reiterate in a real-world US setting that
vaccination with BNT162b2 remains an essential tool for
preventing COVID-19, especially COVID-19-associated
hospital admissions, caused by all current variants of
concern. Along with other emerging evidence,9,14–16,23
our results suggest that despite early effectiveness of
BNT162b2 against delta and other variants of concern,
effectiveness against infection erodes steadily in the
months after receipt of the second dose. Waning
effectiveness and an increased number of infections
6–12 months after the second dose—along with the
potential need for booster doses—was expected given
that lower neutralising antibody titres during this time
period have been observed in immunogenicity studies.34–36
Waning has been observed for both mRNA-based
(Pfizer–BioNTech and Moderna) COVID-19 vaccines,26,27
and is consistent with studies of other coronaviruses.37
Reassuringly, early phase 1 data show that a third booster
dose of the current BNT162b2 vaccine given 6 months
after the second dose elicited neutralising antibody titres
against the original SARS-CoV-2 wild-type strain, beta,
and delta, which were several times higher than after
two primary doses.34,35 Modelling studies have predicted
that these increases in neutralising antibody titres
will restore high amounts of vaccine effectiveness.36
Moreover, early unpublished data from an Israeli health
maintenance organisation (Maccabi Health Services)
suggest that a third booster dose is highly effective in a
setting in which the delta variant accounts for nearly all
cases.38,39 These findings suggest that boosting with the
current BNT162b2 vaccine rather than a delta-specific
construct might be effective. Considerations of booster
doses should also account for COVID-19 supply, as
priority populations in some countries or subnational
settings have not yet received a primary vaccination
series.40
from paragraph 3 -
"Reassuringly, early phase 1 data show that a third booster
dose of the current BNT162b2 vaccine given 6 months
after the second dose elicited neutralising antibody titres
against the original SARS-CoV-2 wild-type strain, beta,
and delta, which were several times higher than after
two primary doses.34,35 Modelling studies have predicted
that these increases in neutralising antibody titres
will restore high amounts of vaccine effectiveness. "36
some of the nonsensical numbers denote footnotes -
it is probably 'splitting hairs' with Multi - that 'boosters' provide immunity beyond that produced with the initial two-dose vaccination - and
And I acknowledge that for the duration of the study, hospitalizations did not increase with a decline in immunity (as indicated by a positive PCR test - I believe
( I see nothing in the study that indicates there was any 'antibody testing' reflected in the study ) .
I agree with Multi- that getting more people vaccinated is more important to controlling the disease.
but unless there is a shortage of vaccine that I am not aware of, it is not a matter of choice
( there is enough vaccine available to vaccinate everyone And give 'boosters' ( a third dose ) )
and I agree with Adolph regarding the side-effects of a third dose. ...
respectfully. tj
postscript -
the study differentiated data by demographic groups -
was my skill or software better, I would post the other half of Figure2 from page seven -
to the argument - the "waning immunity" is comparable across the groups, Except for those Under 17 for whom the data is incomplete.
I will restate that : the data shows immunity wanes similarly across the demographic groups.
Bookmarks